Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer

Breast

Volumn 21, Issue 1, 2012, Pages 40-45

  Takada, Masahiro ^a   Saji, Shigehira ^a,b,c   Masuda, Norikazu ^d   Kuroi, Katsumasa ^c   Sato, Nobuaki ^e   Takei, Hiroyuki ^f   Yamamoto, Yutaka ^g   Ohno, Shinji ^h   Yamashita, Hiroko ⁱ   Hisamatsu, Kazufumi ^j   Aogi, Kenjiro ^k   Iwata, Hiroji ^l   Ueno, Takayuki ^a   Sasano, Hironobu ^m   Toi, Masakazu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e NIIGATA CANCER CENTER HOSPITAL   (Japan)

^f SAITAMA CANCER CENTER   (Japan)

^g KUMAMOTO UNIVERSITY   (Japan)

^h NATIONAL KYUSHU CANCER CENTER   (Japan)

ⁱ NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

^j HIROSHIMA CITY ASA HOSPITAL   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^l AICHI CANCER CENTER HOSPITAL   (Japan)

^m TOHOKU UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Aromatase inhibitor; Body mass index; Breast cancer; Exemestane; Neoadjuvant hormonal therapy; Predictive factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84856338531     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.07.015     Document Type: Article

References (27)

1. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. JClin Oncol 2007, 25:486-492.
2. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45-53.
3. van de Velde C.J., Rea D., Seynaeve C., Putter H., Hasenburg A., Vannetzel J.M. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011, 377:321-331.
4. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. NEngl J Med 2003, 348:1625-1638.
5. Ewertz M., Jensen M.B., Gunnarsdottir K.A., Hojris I., Jakobsen E.H., Nielsen D. Effect of obesity on prognosis after early-stage breast cancer. JClin Oncol 2011, 29:25-31.
6. Protani M., Coory M., Martin J.H. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010, 123:627-635.
7. McTiernan A., Wu L., Chen C., Chlebowski R., Mossavar-Rahmani Y., Modugno F. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obes (Silver Spring) 2006, 14:1662-1677.
8. Dignam J.J., Wieand K., Johnson K.A., Fisher B., Xu L., Mamounas E.P. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. JNatl Cancer Inst 2003, 95:1467-1476.
9. Pfeiler G., Königsberg R., Singer C., Seifert M., Dubsky P., Samonigg H., et al. Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: an analysis of the ABCSG-12 trial. JClin Oncol 2010, 28. abstr512.
10. Sestak I., Distler W., Forbes J.F., Dowsett M., Howell A., Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. JClin Oncol 2010, 28:3411-3415.
11. Toi M., Saji S., Masuda N., Kuroi K., Sato N., Takei H., et al. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Sci 2011, 102:858-865.
12. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz LH., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
13. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
14. Miller W.R., White S., Dixon J.M., Murray J., Renshaw L., Anderson T.J. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 2006, 94:1051-1056.
15. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363:157-163.
16. Hankinson S.E., Willett W.C., Manson J.E., Hunter D.J., Colditz G.A., Stampfer M.J., et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. JNatl Cancer Inst 1995, 87:1297-1302.
17. Mahabir S., Baer D.J., Johnson L.L., Hartman T.J., Dorgan J.F., Campbell W.S., et al. Usefulness of body mass index as a sufficient adiposity measurement for sex hormone concentration associations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006, 15:2502-2507.
18. McTiernan A., Rajan K.B., Tworoger S.S., Irwin M., Bernstein L., Baumgartner R., et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. JClin Oncol 2003, 21:1961-1966.
19. Chumsri S., Howes T., Bao T., Sabnis G., Brodie A. Aromatase, aromatase inhibitors, and breast cancer. JSteroid Biochem Mol Biol 2011.
20. Moon H.G., Han W., Noh D.Y. Underweight and breast cancer recurrence and death: a report from the Korean Breast Cancer Society. JClin Oncol 2009, 27:5899-5905.
21. Conroy S.M., Maskarinec G., Wilkens L.R., White K.K., Henderson B.E., Kolonel L.N. Obesity and breast cancer survival in ethnically diverse postmenopausal women: the Multiethnic Cohort Study. Breast Cancer Res Treat 2011.
22. Loo C.E., Straver M.E., Rodenhuis S., Muller S.H., Wesseling J., Vrancken Peeters M.J. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. JClin Oncol 2011, 29:660-666.
23. James K., Eisenhauer E., Christian M., Terenziani M., Vena D., Muldal A. Measuring response in solid tumors: unidimensional versus bidimensional measurement. JNatl Cancer Inst 1999, 91:523-528.
24. Park J.O., Lee S.I., Song S.Y., Kim K., Kim W.S., Jung C.W. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003, 33:533-537.
25. Gasparini G., Pozza F., Meli S., Reitano M., Santini G., Bevilacqua P. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Res 1991, 11:2015-2021.
26. Sahin A.A., Ro J., Ro J.Y., Blick M.B., el-Naggar A.K., Ordonez N.G. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 1991, 68:549-557.
27. Weidner N., Moore D.H., Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol 1994, 25:337-342.